PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

36,300 stories, page 114 of 605

Advanced search
🇺🇸Researchclinicaltrials.gov

NCT06717334: A Study of Lung Cancer Screening in People With Unexplained Weight Loss

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06526338: Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06414408: Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

Study type: INTERVENTIONAL. Phase: EARLY_PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06364410: Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06333392: Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06295679: A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06126224: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06112613: Mobile Health for Adherence in Breast Cancer Patients

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT06062498: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT05990946: Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT05933174: Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT05906004: Post-Market Clinical Follow-up (PMCF) Study of the Pitch-Patch for the Augmentation or Reinforcement of the Rotator Cuff

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT05761782: Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT05688605: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT05198830: Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT04815356: Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT04230356: Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT01972919: MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.gov

NCT00001778: Evaluation of Patients With HAM/TSP

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🌍discoverynews.google.com

GC Green Cross Receives IND Approval for Phase 2/3 Clinical Trial of High-Immunogenicity Influenza Vaccine

아시아경제Original source
🌍discoverynews.google.com

Biotech company Diatherix plans layoffs

The Business JournalsOriginal source
🌍discoverynews.google.com

Up to 20% of children with Dravet syndrome die before adulthood. A long-term study of an experimental drug showed fewer severe seizures.

Stock TitanOriginal source
🌍discoverynews.google.com

BIG Executive Summit: Lasting Impacts on Biotech Adoption

BioProcess InternationalOriginal source
🌍discoverynews.google.com

Heartland BioWorks tackles Indiana’s biotech labor shortage

BioProcess InternationalOriginal source
🌍discoverynews.google.com

South Korean Biotech Licensing Deals Top ₩21 Trillion, but Stock Prices Lag — Recovery Hinges on Market Liquidity

finance.biggo.comOriginal source
🌍discoverynews.google.com

FDA Approves First Drug to Treat Alexander Disease

finchannelOriginal source
🌍discoverynews.google.com

Polyrizon raises $4M as intranasal hydrogel biotech taps single investor

app.dealroom.coOriginal source
🌍discoverynews.google.com

Viral infections biotech ENA Respiratory inhales $3 million from government fund

Startup DailyOriginal source
🌍discoverynews.google.com

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

The Motley FoolOriginal source
🌍discoverynews.google.com

EXCLUSIVE: AI, Genomics Could Fuel Biotech ETF Re-Rating as Health Care Trades at Discount, Says Expert

BenzingaOriginal source
🌍discoverynews.google.com

GLP-1 Drugs Tied to Higher Male Pattern Hair Loss Risk

labroots.comOriginal source
🇪🇸Researchcnic.es

Science Immunology: El secreto de los tejidos que más trabajan: una buena limpieza

CNIC Spain CardiovascularOriginal source
🇪🇸Researchcnic.es

Nature Medicine: Un estudio establece el papel de los nuevos tratamientos para la amiloidosis cardiaca por transtiretina

CNIC Spain CardiovascularOriginal source
🇪🇸Researchcnic.es

CNIC y la Fundación Ramón Areces organizan la segunda conferencia internacional para comprender la red neurovascular y prevenir la demencia

CNIC Spain CardiovascularOriginal source
🌍discoverynews.google.com

Nuvectis Pharma draws top biotech funds after $115M raise

app.dealroom.coOriginal source
🇮🇹Researchpoliclinico.mi.it

#CONVEGNO [16.09] POLICLINICO KIDS 2.0

Policlinico di MilanoOriginal source
🌍discoverynews.google.com

Yuce Biotech raises $7.4M Series B for single-molecule immunodiagnostics

DealroomOriginal source
🌍discoverynews.google.com

Frost & Sullivan Released the 2026 Blue Book on the Development of Hong Kong Stock Exchange 18A Biotech Sector

wkow.comOriginal source
🌍discoverynews.google.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group

MarketBeatOriginal source
🌍discoverynews.google.com

FDA Approves Zilganersen Injection, First Drug for Alexander Disease

Pharmacy TimesOriginal source
🌍discoverynews.google.com

Eascra Biotech expands Worcester presence following $8M NASA award

Worcester Business JournalOriginal source
🌍discoverynews.google.com

Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder

STATOriginal source
🌍discoverynews.google.com

FDA abortion pill challenge delayed until after midterms

Pregnancy Help NewsOriginal source
🌍discoverynews.google.com

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

The Manila TimesOriginal source
🌍discoverynews.google.com

Former Pfizer vaccine chief joins Vaxcyte. Trial data is expected by October’s end.

Stock TitanOriginal source
🌍Industryinvestors.vivani.com

Vivani Medical Announces Participation in Upcoming Investor Conferences

Vivani MedicalOriginal source
🌍discoverynews.google.com

US Government Moves To Counter Ex-US R&D

DCAT Value Chain InsightsOriginal source
🌍Medialemsurgical.com

Autonomous Robotics: Why Aviation Precedes the Automotive Industry and Its Relevance to Surgery

LEM Surgical (Dynamis Spine Robot)Original source
🌍Industrytreace.com

SuperBite™ – Dr. Cavovarus

Treace Medical ConceptsOriginal source
🌍Industrytreace.com

SuperBite™ – Dr. Kaplan

Treace Medical ConceptsOriginal source
🌍Industrytreace.com

SuperBite™ – Dr. Vulcano

Treace Medical ConceptsOriginal source
🇧🇷Industryems.com.br

Top 30 – As Melhores Empresas do Brasil 2026

EMS Pharma NewsOriginal source
🇧🇷Industryems.com.br

EMS e Abrasso realizam campanha contra osteoporose, com exames gratuitos, na estação Brás, da CPTM

EMS Pharma NewsOriginal source
🌍discoverynews.google.com

Federal judge delays mifepristone lawsuit until after midterms

EWTN NewsOriginal source
🌍discoverynews.google.com

First patient dosed in OCU410 phase 3 trial for geographic atrophy

Ophthalmology TimesOriginal source
🇧🇷Industryems.com.br

EMS é patrocinadora da Orquestra Sinfônica Municipal de Paraty

EMS Pharma NewsOriginal source
🇺🇸Researchwi.mit.edu

Tenure-Track Faculty Position at Whitehead Institute and the Massachusetts Institute of Technology

Whitehead Institute NewsOriginal source
🌍discoverynews.google.com

Ultragenyx's Apazunersen Fails Phase III Trial | PharmExec

Pharmaceutical ExecutiveOriginal source